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respondents (of 53,524 total) using 1–2 (n = 6,434), 3–4 (5,529), or 5+ (5,727) pre-
scription medications for symptomatic conditions. Adherence was higher among those 
who saw a GP in the past 6 months (M = 1.19, SD = 1.24, n = 14,802) vs. those who 
did not (M = 1.36, SD = 1.29, n = 2,888), P < 0.001, and higher among those with 
a higher number of prescriptions (for 5+, 3–4, and 1–2: Ms = 0.99, 1.26, and 1.38; 
SDs = 1.18, 1.26, and 1.27, respectively), P < 0.001. Hospitalizations were lower 
among GP visitors (M = 0.30, SD = 2.39) than non-visitors (M = 0.34, SD = 2.07), P 
< 0.001, ER visits were lower among GP visitors (M = 0.32, SD = 1.20) than non-
visitors (M = 0.33, SD = 2.09), P < 0.001, and both were signiﬁ cantly higher among 
those with more prescriptions, ps < 0.001. The beneﬁ ts of a GP were largely indepen-
dent of number of medications. CONCLUSIONS: Among European patients taking 
prescriptions, visiting a GP was associated with greater adherence and lower health 
care resource utilization.
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OBJECTIVES: The aim of this study is to answer the following questions: 1) How 
high is the self-reported nonadherence (NA) of German patients with the need to regu-
larly take medication? and 2) Which factors capable of explaining this self-reported 
NA can be identiﬁ ed by multivariate analysis? METHODS: Two cross-sectional 
surveys (phone survey with 1177 patients; face-to-face in-depth survey with 340 
patients in 17 German pharmacies) were conducted. Self-reported NA was measured 
by the generic Morisky scale (either as 4 items or 8 item MMAS). Identiﬁ cation of 
explanatory factors was conducted on the basis of multivariate logistic regression 
analysis (including the calculation of additive risks by dichotomization of signiﬁ cant 
explanatory factors). RESULTS: 1) Approximately 35–40 % of the patients can be 
described as non-adherent (38.8 %/35.3 %); 2a) Survey 1: Only a few socio-demo-
graphic factors are able to explain the NA (chronic disease, some aspects of age, and 
low number of required medications to take); and 2b) Survey 2: Most results of the 
ﬁ rst survey can be replicated. However, intentional NA explanations have consider-
ably more inﬂ uence: positive medication belief, a positive mood, and a good patient-
doctor relationship reduce the NA risk. Furthermore, patients who are easily able to 
recognize the correct medication on the basis of the identiﬁ cation of the packaging 
have a signiﬁ cantly reduced NA probability. When additive risk is considered, patients 
who are chronically ill but display no other risk factors have an NA probability rate 
of 10.4 %, for patients displaying all identiﬁ ed risk factors this rate increases to 93.9 
%. CONCLUSIONS: Our surveys are the largest and most detailed to have been 
conducted in Germany concerned with the theme of medication-based NA. Our results 
show that approximately one-third of patients can be classiﬁ ed as non-adherent. 
Intentional NA factors explain the NA considerably better than do socio-economic 
factors.
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OBJECTIVES: A regional health plan implemented a specialty pharmacy beneﬁ t with 
increased copayment/coinsurance for specialty medications. Our objective was to 
measure and compare the change in adherence and persistence after implementation 
of the specialty beneﬁ t. METHODS: Pharmacy claims for patients who chronically 
used anti-inﬂ ammatory, immunosuppressant, cancer, and multiple sclerosis medica-
tions were assessed. The intervention group consisted of those whose out-of-pocket 
cost-share for specialty medications increased by at least $25 (per 30-day ﬁ ll), and the 
control group consisted of those whose out-of-pocket amounts did not change. Adher-
ence, deﬁ ned by proportion of days covered (PDC), was measured every 3 months for 
12 months before and after the copay change. Paired t-tests compared the adherence 
in the pre- vs. post-periods. Individual growth model analysis evaluated the changes 
in adherence throughout the time periods. Cox regression analysis determined the 
difference in persistence between groups after the copay change, controlling for age, 
gender, copay level, group, and pre-period persistence. RESULTS: There were 237 
patients in the intervention group and 211 patients in the control group. The PDC 
results varied by drug type; adherence decreased after the copay change in the interven-
tion group for patients on anti-inﬂ ammatory, immunosuppressant, and multiple scle-
rosis medications, but remained consistent for patients on antineoplastics. The growth 
model showed a small, but statistically signiﬁ cant decrease in PDC of 0.01 after copay 
changes (P = 0.014). The Cox regression analysis indicated that the estimated risk of 
discontinuing therapy increased for patients in the intervention vs. control groups 
(hazard ratio = 2.35, 95% CI: 1.43–3.58). CONCLUSIONS: The move to the specialty 
pharmacy beneﬁ t allows for closer scrutiny of specialty utilization by pharmacists who 
actively monitor utilization and access. Despite the minimal adherence decrease and 
signiﬁ cant persistence changes, the results indicated relatively more stability with the 
use of specialty medications than that reported with copayment/coinsurance increases 
for traditional pharmaceutics.
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OBJECTIVES: Women with PMO are most often treated with bisphosphonates (BPs), 
as well as with strontium ranelate (SR) and raloxifene (RLX). However, a high per-
centage of patients are not persistent after 1 year of therapy, which can compromise 
treatment effectiveness (Imaz I, Osteoporos Int 2010) and thus increase the risk of 
fractures. The objective was to estimate the persistence to PMO treatments in a region 
of Spain (Catalonia) representative of the Spanish population. METHODS: This 
database analysis included women with PMO from 6 primary care centers, aged ≥50 
years who initiated BPs (alendronate, ibandronate, risedronate), SR or RLX between 
January 1, 2004 and June 30, 2008. Patients with cancer, other bone diseases, hospi-
talization >30 days or <1 year follow-up data were excluded. Persistence was measured 
at 1, 2 or 3 years according to prescriptions dispensed at ofﬁ ce-based pharmacies. 
Three patients’ cohorts were analyzed: patients with ≥1 year (cohort 1), ≥2 years 
(cohort 2) and ≥3 years (cohort 3) follow-up. Patients with no access to medication 
for >1 month were considered non-persistent and a switch to another PMO treatment 
was considered a discontinuation. In a secondary analysis, switch was not considered 
a discontinuation. Statistics were performed using Kaplan-Meier methodology. 
RESULTS: A total of 3,049 patients (mean age ± SD; 68.3 ± 9.7 years) were included 
in cohort 1; 30% were persistent after 1 year (95%CI:27.5–32.5). In cohort 2 (n = 
2698; 68.9 ± 9.3 years) persistence was 35% (CI:32.6–36.2) and 16% (CI:13.6–19.2) 
after 1 and 2 years respectively. In cohort 3 (n = 2163; 68.4 ± 9.5 years) persistence 
was 36% (CI:33.9–37.9), 20% (CI:18.3–21.7) and 9% (CI:5.9–12.1) after 1, 2 and 
3 years, respectively. The results were similar by drug and frequency of administration, 
and also when switch was not considered a discontinuation. CONCLUSIONS: In this 
Spanish population of postmenopausal women with osteoporosis, persistence to treat-
ment was poor, even when a switch was not considered a discontinuation.
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OBJECTIVES: Our study focused on revealing difﬁ culties in maintaining balance 
during pregnancy. METHODS: Balance testing was performed on 150 volunteers (50 
healthy pregnant, 50 pathologically pregnant, 50 healthy young non—pregnant 
women). One hundred pregnant women were allocated into 4 subgroups based on 
physical activity performed prior to and during pregnancy. During stabilometer mea-
surements static balance was examined with Romberg test while dynamic balance with 
5 programs on a stabilometer. Statistical data were calculated according to mean, 
standard deviation and T-test while the results were considered to be relevant at P < 
0,05. RESULTS: Average results of Romberg test were worse in groups of pregnant 
women compared to non-pregnant women although the difference was not signiﬁ cant. 
Concerning the subgroups: those who had previously been involved in professional 
sports and were healthy and physically active during pregnancy performed better on 
the open–eye test (P < 0,05) compared to pathologically pregnant patients. Between 
the second and third trimesters of healthy pregnancies no signiﬁ cant results were found 
in Romberg test while a signiﬁ cant difference was detected (P < 0,05) in the perfor-
mance of the 5th exercise of the dynamic balance test. Regarding the 5 programs on 
the stabilometer examining dynamic balance non-pregnant women performed all 
exercises signiﬁ cantly better (P < 0,05) than healthy pregnant women. However when 
compared to pathologically pregnant women apart from the exercises No.2 the result 
showed a signiﬁ cant difference (P < 0,05). Concerning the same exercises healthy 
pregnant women performed signiﬁ cantly better (P < 0,05) in exercises No.1 and No.4. 
Pregnant women who had previously been and remained physically active during 
pregnancy performed the exercise of moving the centre of body weight in a signiﬁ -
cantly shorter time than those who were inactive and hospitalised. CONCLUSIONS: 
Statistical analysis of data proves that physical activity (especially professional sports) 
prior to becoming pregnant and physical activity during pregnancy have positive 
effects.
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OBJECTIVES: Treatments to prevent prostate cancer are associated with side effects 
and the impact of these on health related quality of life (HRQL) should be considered 
in any assessment of cost-effectiveness. However our systematic review identiﬁ ed a 
lack of robust data. a prospective assessment of the impact of side effects was under-
taken using generic and condition-speciﬁ c measures of HRQL. METHODS: Partici-
pants were recruited from an online panel. Men over 55, with either erectile 
dysfunction (ED), loss of libido, gynecomastia or ejaculatory disorders (without other 
chronic disease such as renal failure, diabetes, multiple sclerosis etc), and an age 
matched control group completed assessments of symptom severity and HRQL 
(EQ-5D and Sexual QoL survey—SQoL-3D). Both HRQL measures can provide 
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utility estimates. Regression models (tobit, OLS, Censored least absolute deviation) 
were used to estimate speciﬁ c changes in HRQL associated with the side effects. 
RESULTS: Many participants reported more than one symptom, with ED most 
common (n = 139); reduced libido (n = 99); ejaculatory disorder (n = 98), and gyne-
comastia (n = 20). From the OLS regression EQ-5D and SQoL-3D disutilities were 
estimated for ED (−0.042; −0.075); reduced libido (−0.053; −0.047); ejaculatory dis-
order (−0.046; −0.028), and gynecomastia (−0.045; −0.037) respectively. EQ-5D and 
SQoL-3D were weakly correlated (r = 0.296). CONCLUSIONS: The condition-speciﬁ c 
and generic estimates indicate the impact of prostate-related preventative treatment 
on HRQL. While the magnitude of disutilities is similar the poor correlation between 
the two measures suggests they are measuring different aspects of HRQL. The value 
of condition-speciﬁ c versus generic methods for estimating utilities will be discussed.
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OBJECTIVES: The Sexual Function Questionnaire (SFQ-28) is a well established and 
validated self-reported screening and outcomes measure of female sexual dysfunction 
(FSD). In order to reduce patient burden and focus on symptoms of FSD, two domains 
(partner and enjoyment) have been removed to create an abbreviated version (ASFQ). 
The objective of this study was to ensure that the removal of these domains had not 
changed the psychometric properties of the measure. METHODS: Forty seven pre-
menopausal women with diagnosed female sexual arousal disorder (FSAD), primarily 
cognitive arousal difﬁ culties, completed the ASFQ, the Women’s Sexual Distress 
Questionnaire (WSDQ), an FSAD daily diary and a meaningful beneﬁ t question 
(MBQ) as part of a double-blind, placebo-controlled, 3-way crossover trial. Baseline 
data were used to assess internal consistency and convergent validity (with the FSAD 
diary). Known groups validity (comparing those with high versus low levels of distress 
on the WSDQ at end of treatment) and responsiveness of the arousal domains of ASFQ 
were also assessed. RESULTS: The ASFQ domains demonstrated excellent internal 
consistency with Cronbach’s alpha ranging from 0.73 to 0.89. All ASFQ domains 
showed excellent convergent validity with the respective items on the FSAD diary. 
Excellent known groups validity was demonstrated for the desire and arousal cognitive 
domains with those with higher distress scores showing poorer scores on these dimen-
sions of the ASFQ. Moderate effect sizes were observed in the arousal domains for 
those who indicated they had a meaningful improvement in their arousal disorder 
during the trial. CONCLUSIONS: The results conﬁ rm that the removal of two 
domains from the SFQ-28 has not impacted on its psychometric properties or respon-
siveness. The ASFQ is recommended for use in studies where patient burden needs to 
be minimized.
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OBJECTIVES: The objective of this qualitative interview study was to assess the 
content validity of the BII in a sample of men with signs and symptoms of BPH using 
concept elicitation (CE) and cognitive interviewing (CI) methods. METHODS: Fifty 
men with BPH participated in the study; 27 completed the CEs and 23 completed the 
CIs. CEs were semi-structured asking subjects to describe the BPH symptoms they 
experience and how symptoms impact their life. CIs were semi-structured, asking 
subjects to describe their 1) difﬁ culties completing the BII; 2) understanding of item 
meaning and terminology; 3) understanding of response options; and 4) ability to 
respond appropriately to the speciﬁ ed recall period. All interviews were audio recorded 
and transcribed. Data was analyzed using Atlas.ti. a saturation table was used to 
identify when no new concepts were forthcoming. Inter-rater agreement (IRA) was 
evaluated by having three coders independently dual-code 3 (11%) transcripts. Con-
sistency of coding was characterized by agreement in the identiﬁ cation of concepts, 
and agreement in assignment of codes. RESULTS: Saturation of concepts was reached 
by the completion of 21 CE interviews. High agreement on coding consistency was 
achieved at 69.4 to 89.4% for identiﬁ cation of concepts, and 87.8 to 96% for assign-
ments of codes. The BII was shown to be readily understandable and easily completed 
in a short period of time, and supported by the qualitative results as measuring the 
relevant impacts related to BPH. CONCLUSIONS: The BII shows strong evidence of 
content validity and provides an assessment of disease-related, clinically meaningful 
impacts of BPH symptoms and treatment outcomes in BPH studies.
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OBJECTIVES: Translation and linguistic validation of patient reported outcomes 
(PRO) measures is an essential component of research methodology in preparation 
for multinational clinical trials. The Injection Pen Assessment Questionnaire (IPAQ) 
is a dyadic (parent and child together) or self-report of ease of use and preference tool 
that allows objective and normative comparisons across and between injection pens 
used to administer human growth hormone (hGH). The purpose of this work was to 
translate and linguistically validate the IPAQ, which was developed in English in the 
United States, for use in 7 countries: Czech Republic, Germany, The Netherlands, 
Slovakia, Sweden, Turkey and United Kingdom. METHODS: The IPAQ was trans-
lated according to industry standard methodology. Five parent-child dyads (children 
8 to 18 years old) per country completed the respective translated questionnaire and 
participated in a cognitive interview. Interviews were conducted using a standardized 
guide to assess the relevance, understandability, and appropriateness of the wording 
of the translations. Qualitative analyses were performed to ensure equivalence and 
that the content validity of the IPAQ was maintained across language versions. 
RESULTS: The study sample consisted of 35 parent-child dyads who use injection 
devices to administer hGH (42.8% male). Mean age of the children was 12 years. The 
sample consisted of patients who speak 7 languages collectively. All IPAQ items were 
well understood and proved relevant to the patients in this sample. Of interest, terms 
such as, “cartridge”, “needle guard” and “injecting the medicine” were understood 
similarly by participants across countries. CONCLUSIONS: The results indicate the 
IPAQ translations were conceptually equivalent to the English source version and 
easily understood by the target population in all countries. We consider these transla-
tions acceptable for PRO assessment in international research, clinical practice and 
clinical trials.
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WOMEN UNDERGOING OVARIAN STIMULATION: ELABORATION AND 
VALIDATION OF VENUSF QUESTIONNAIRE
Espallardo O1, Ruiz-Balda J2, Carrera M2, Caballero J3, Polanco C1, Bruna I4, Hernández 
C5, Cuadrado C6, Carrillo E7, Ordóñez D7, García-Velasco J8, Serna J8, Galera F9, Zafra 
J10, Caballero P11, Hernández E3, Fuente A12
1Merck Serono, Madrid, Spain; 2Hospital Universitario Doce de Octubre, Madrid, Spain; 
3Clínica FIV, Madrid, Spain; 4Hospital de Madrid Montepríncipe, Madrid, Spain; 5Fundación 
Jiménez Díaz, Madrid, Spain; 6Hospital Universitario La Paz, Madrid, Spain; 7Hospital Ruber 
Internacional, Madrid, Spain; 8IVI Madrid, Madrid, Spain; 9Instituto Madrileño de Fertilidad, 
Madrid, Spain; 10Hospital General Universitario Gregorio Marañón, Madrid, Spain; 11Clínica 
Tambre, Madrid, Spain; 12Instituto Europeo de Fertilidad, Madrid, Spain
OBJECTIVES: To elaborate and validate a questionnaire on patient satisfaction with 
the follitropin alfa preﬁ lled pen, compared with previously used injectable gonadotro-
pins, in women undergoing ovarian stimulation. METHODS: VENUsf questionnaire 
with 14 items was constructed after a four-stage process (concept identiﬁ cation and 
item generation; item review by an expert on female infertility; patients interview; and 
editing of questionnaire according to interviews results) in which both experts on 
health outcomes research and fertility professionals and patients were involved. a 
post-authorization observational study (non-randomised patients, national setting) 
was undergone in order to validate the questionnaire. After assessing sample adequacy 
(Kaiser-Meyer-Olkin index and Bartlett’s test of sphericity), Rasch analysis (inﬁ t and 
outﬁ t statistics) provided a reduced version of the questionnaire. Its psychometric 
properties were assessed: feasibility (omitted response and time to fulﬁ l it), variability 
(ﬂ oor and ceiling effects), validity (factor analysis and nonparametric tests) and reli-
ability (Cronbach’s alpha). RESULTS: Initial questionnaire (14 items and 6 additional 
questions) was answered by 91.1% of sample (n = 107) in an average of 5.04 minutes 
(SD = 3.3). Statistical correlation was observed between scores from two dimensions 
of questionnaire and overall treatment satisfaction, as well as variables Number of 
previous treatments, Time since last treatment and Minutes required to prepare pen. 
Rasch analyses yield 9 items in the ﬁ nal version of the questionnaire. This process was 
conﬁ rmed by sample adequacy (KMO = 0.72, statistically signiﬁ cant value of Bartlett’s 
test of sphericity) and reliability parameters (Cronbach’s alpha = 0.78). CONCLU-
SIONS: The reduced version of the questionnaire VENUsf a feasible, valid and reliable 
tool for assessing patient satifaction with follitropin alfa preﬁ lled pen in women 
undergoing ovarian stimulation.
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OBJECTIVES: To assess the perceptions of the general public in Malaysia about the 
importance of drug labeling. METHODS: A cross sectional study using pre-validated 
questionnaire was undertaken with a convenient sample of general public in the State 
of Penang, Malaysia. All data was analyzed using SPSS for Windows version 12.0. 
Inferential statistics were used whenever appropriate at alpha value of 0.05 or less 
considered signiﬁ cant. RESULTS: A total of 365 respondents had participated in the 
survey. Majority of them agreed that drug labeling is important to any person dispens-
ing medicines (74.8%), caretakers (76.26%), health care professionals (77.8%) and 
patients (80.6%). Besides, they believed that it is important to ensure all drug labels 
are not vaguely claimed to improve quality of life (54.2%). Majority of respondents 
agreed that incorrect dosage instructions on the drug label would result in worsening 
the quality of life (73.2%). Majority of respondents (58.4%) believed that drug label-
ing is highly important to ensure safe and effective drug use. Majority also expected 
that all drug products and controlled medicines should be labeled with product name 
(97.5%), active ingredients (78%), date of manufacture and expiry (87%), and dosage 
